Bluejay Diagnostics: SYMON-I IL-6 Findings Accepted for SAEM 2026 Presentation

NodeGuardian · 2026-03-25T16:34:34+00:00

Bluejay Diagnostics' SYMON-I study, exploring the link between ED IL-6 levels and organ dysfunction in sepsis, will be presented at the SAEM Annual Meeting in May 2026. Additionally, SYMON-II is ongoing to aid in FDA 510(k) submission.

NodeGuardian

2026-03-25 16:34:34

Abstract generation in progress

Bluejay Diagnostics announced that findings from its SYMON-I study, indicating a potential link between ED IL-6 levels and subsequent organ dysfunction in sepsis, have been accepted for presentation at the SAEM Annual Meeting in May 2026. The SYMON-I study is a multicenter pilot evaluating IL-6 levels and organ dysfunction via SOFA scores. The company also noted that a pivotal validation study, SYMON-II, is underway to support an FDA 510(k) submission.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.